Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience

Simple item page
dc.contributor.advisorMyer, Landonen_ZA
dc.contributor.advisorWatermeyer, Gillen_ZA
dc.contributor.authorSetshedi, Mashikoen_ZA
dc.date.accessioned2014-11-07T10:10:15Z
dc.date.available2014-11-07T10:10:15Z
dc.date.issued2008en_ZA
dc.descriptionIncludes bibliographical references (leaves 55-63).en_ZA
dc.description.abstractThe benefits of the use of Azathioprine (AZA) and its metabolite 6-mercaptopurine (6-MP) in the treatment of Inflammatory Bowel Disease (IBD) are well established. However, concern regarding the long-term use of these agents in the induction of certain malignancies particularlty lymphoma and skin cancer has been reported in renal transplant and rheumatoid arthritis patients. In IBD patients hoever, several retropsective and prospective studies have been conducted (including two meta-analyses) with divergent results. The primary objective of this study was to compare the incidence of cancer in IBD patients treated with AZA/6BMP with those not treated. Secondary objectives were to assess if skin cancer had a higher incidence of occurrence than other cancers, and to determine the independent risk factors associated with cleveloping any malignancy.en_ZA
dc.identifier.apacitationSetshedi, M. (2008). <i>Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience</i>. (Thesis). University of Cape Town ,Faculty of Health Sciences ,Department of Public Health and Family Medicine. Retrieved from http://hdl.handle.net/11427/9317en_ZA
dc.identifier.chicagocitationSetshedi, Mashiko. <i>"Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience."</i> Thesis., University of Cape Town ,Faculty of Health Sciences ,Department of Public Health and Family Medicine, 2008. http://hdl.handle.net/11427/9317en_ZA
dc.identifier.citationSetshedi, M. 2008. Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience. University of Cape Town.en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Setshedi, Mashiko AB - The benefits of the use of Azathioprine (AZA) and its metabolite 6-mercaptopurine (6-MP) in the treatment of Inflammatory Bowel Disease (IBD) are well established. However, concern regarding the long-term use of these agents in the induction of certain malignancies particularlty lymphoma and skin cancer has been reported in renal transplant and rheumatoid arthritis patients. In IBD patients hoever, several retropsective and prospective studies have been conducted (including two meta-analyses) with divergent results. The primary objective of this study was to compare the incidence of cancer in IBD patients treated with AZA/6BMP with those not treated. Secondary objectives were to assess if skin cancer had a higher incidence of occurrence than other cancers, and to determine the independent risk factors associated with cleveloping any malignancy. DA - 2008 DB - OpenUCT DP - University of Cape Town LK - https://open.uct.ac.za PB - University of Cape Town PY - 2008 T1 - Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience TI - Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience UR - http://hdl.handle.net/11427/9317 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/9317
dc.identifier.vancouvercitationSetshedi M. Risk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experience. [Thesis]. University of Cape Town ,Faculty of Health Sciences ,Department of Public Health and Family Medicine, 2008 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/9317en_ZA
dc.language.isoengen_ZA
dc.publisher.departmentDepartment of Public Health and Family Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.subject.otherPublic Healthen_ZA
dc.titleRisk of malignancy in patients with inflammatory bowel disease treated with Azathioprine or 6-mercaptopurine : the Cape Town experienceen_ZA
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMPHen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hsf_2008_setshedi_m.pdf
Size:
5.23 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Masters